dc.creatorSuresh Chalichem, Nehru Sai
dc.creatorBethapudi, Bharathi
dc.creatorMundkinajeddu, Deepak
dc.date.accessioned2020-08-24T14:25:11Z
dc.date.accessioned2022-09-23T18:41:59Z
dc.date.available2020-08-24T14:25:11Z
dc.date.available2022-09-23T18:41:59Z
dc.date.created2020-08-24T14:25:11Z
dc.identifier0306-9877
dc.identifierhttps://doi.org/10.1016/j.mehy.2020.109984
dc.identifierhttp://hdl.handle.net/20.500.12010/12133
dc.identifierhttps://doi.org/10.1016/j.mehy.2020.109984
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3505788
dc.description.abstractIn the current COVID-19 pandemic, prioritizing the immunity enhancers is equally important to anti-virals. Defensins are the forgotten molecules that enhance the innate immunity against various microbes. Although macrolides like azithromycin and clarithromycin etc., have been reported to act against respiratory infections but they lack the ability of immunity enhancement through defensins. The aminoglycosides were proved to have defensin mediated antiviral activity, that could enhance the immunity. So, Consideration of aminoglycosides can be a double edge sword viz., against respiratory infection as well as Immunity enhancer (along with anti-virals) for COVID-19 regimen.
dc.languageeng
dc.publisherMedical Hypotheses
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.rightsAcceso restringido
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subjectCOVID-19
dc.subjectRepurposing strategy
dc.subjectInnate immunity
dc.subjectDefensins
dc.subjectAndrographis
dc.titleAminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy


Este ítem pertenece a la siguiente institución